-
Patient Preference and Adherence
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Predictors of premature discontinuation of treatment in multiple disease states
Original Research
(2322) Views (519) Full article downloads
Authors: Eric Nantz, Hong Liu-Seifert, Vladimir Skljarevski
Published Date January 2009
Volume 2009:3 Pages 31 - 43
DOI: http://dx.doi.org/10.2147/PPA.S4633
Eric Nantz1, Hong Liu-Seifert2, Vladimir Skljarevski2
1Department of Statistics, Western Michigan University, Kalamazoo, MI, USA; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
Background: Premature discontinuation of treatment impacts outcomes of clinical practice. The traditional perception has been patient discontinuation is mainly driven by unwanted side effects. Systematic analysis of data from clinical trials across several disease states was performed to identify predictors of premature discontinuation during clinical interventions.
Methods: A post hoc analysis was conducted on 22 randomized, double-blind, placebo-controlled clinical trials for treatment of fibromyalgia, diabetic peripheral neuropathic pain, major depressive disorder, and generalized anxiety disorder. Analyses were conducted on pooled data within each disease state.
Results: Lack of early therapeutic response was a significant predictor of patient discontinuation in each disease state. Visit-wise changes in therapeutic response and severity of adverse events were also significant risk factors, with change in therapeutic response having a higher significance level in three disease states. Patients who discontinued due to adverse events had similar therapeutic responses as patients completing treatment.
Conclusion: Contrary to the conventional belief that premature treatment discontinuation is primarily related to adverse events, our findings suggest lack of therapeutic response also plays a significant role in patient attrition. This research highlights the importance of systematic monitoring of therapeutic response in clinical practice as a measure to prevent patients’ discontinuation from pharmacological treatments.
Keywords: attrition, depression, generalized anxiety disorder, fibromyalgia, therapeutic response, adverse event
- 8th Annual Patient Adherence, Communications & Engagement Summit
31 May - 1 June 2011, Hotel Concorde, Berlin
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Health literacy and health seeking behavior among older men in a middle-income nation
- Increasing access to quality health care for the poor: Community perceptions on quality care in Uganda
- Prolonged rupture of membranes in term infants: should all babies be screened?
- Narcissistic rage: The Achilles’ heel of the patient with chronic physical illness




